CRYSTALLINE ANTI-hTNFα ANTIBODY

摘要

PROBLEM TO BE SOLVED: To provide a crystallization method which develops a batch crystallization condition to be appropriate for an anti-hTNF-α antibody, especially for human anti-hTNF-α antibody D2E7, establishes a crystallization process condition to be applicable to capacity that is appropriate for industrial antibody crystal production, and does not use a toxic substance which has a possibility to badly affect availability as a pharmaceutical of such an antibody at the same time.SOLUTION: There is provided a method for obtaining a crystal of a complete anti-hTNF-α antibody at batch crystallization capacity exceeding a microliter scale by utilizing a physiologically acceptable inorganic phosphate as a crystallization inducer. An antibody crystal obtained by the method, a composition containing the crystal, and a method of use of the crystal and the composition are also provided.